Subdural Levels of Interleukin 1-receptor Antagonist are Elevated in Patients with Recurrent Chronic Subdural Hematomas

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

Subdural Levels of Interleukin 1-receptor Antagonist are Elevated in Patients with Recurrent Chronic Subdural Hematomas. / Jensen, Thorbjørn Søren Rønn; Binderup, Tina; Olsen, Markus Harboe; Kjaer, Andreas; Fugleholm, Kåre.

In: Inflammation, Vol. 46, 2023, p. 1332–1342.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Jensen, TSR, Binderup, T, Olsen, MH, Kjaer, A & Fugleholm, K 2023, 'Subdural Levels of Interleukin 1-receptor Antagonist are Elevated in Patients with Recurrent Chronic Subdural Hematomas', Inflammation, vol. 46, pp. 1332–1342. https://doi.org/10.1007/s10753-023-01811-8

APA

Jensen, T. S. R., Binderup, T., Olsen, M. H., Kjaer, A., & Fugleholm, K. (2023). Subdural Levels of Interleukin 1-receptor Antagonist are Elevated in Patients with Recurrent Chronic Subdural Hematomas. Inflammation, 46, 1332–1342. https://doi.org/10.1007/s10753-023-01811-8

Vancouver

Jensen TSR, Binderup T, Olsen MH, Kjaer A, Fugleholm K. Subdural Levels of Interleukin 1-receptor Antagonist are Elevated in Patients with Recurrent Chronic Subdural Hematomas. Inflammation. 2023;46:1332–1342. https://doi.org/10.1007/s10753-023-01811-8

Author

Jensen, Thorbjørn Søren Rønn ; Binderup, Tina ; Olsen, Markus Harboe ; Kjaer, Andreas ; Fugleholm, Kåre. / Subdural Levels of Interleukin 1-receptor Antagonist are Elevated in Patients with Recurrent Chronic Subdural Hematomas. In: Inflammation. 2023 ; Vol. 46. pp. 1332–1342.

Bibtex

@article{f77ae2eec6054340b99d62d2fa7b28a2,

title = "Subdural Levels of Interleukin 1-receptor Antagonist are Elevated in Patients with Recurrent Chronic Subdural Hematomas",

abstract = "Anti-inflammatory treatment reduces the risk of recurrent chronic subdural hematoma (CSDH), but clinical implementation is improper due to side effects. Exact knowledge of subdural molecules involved in recurrent CSDH may lead to targeted medical treatment and possibly improve the prospect of a personalized approach by eliminating the broad use of anti-inflammatory drugs on the entire CSDH population. With this study, we aim to (1) describe the associations between cytokine levels at the primary surgery and the risk of subsequent recurrence and (2) describe the association between cytokines in patients with recurrent CSDH between the first and second operations. Systemic and subdural levels of pro- and anti-inflammatory cytokines were measured and compared between patients with the first-time CSDH and recurrent CSDH. Cytokine levels were analyzed using a multiplex antibody bead kit. In case of recurrent CSDH within 90 days of follow-up, the samples were re-collected and analyzed. We included 101 adult CSDH patients of which 20 had a recurrence. The levels of cytokines in the CSDH fluid from patients who were operated on for the first-time CSDH were not associated with the risk of later developing a recurrence. We found interleukin-1 receptor antagonist (IL-1ra) to be elevated in subdural fluid in patients with recurrent CSDH at the time of their second operation (p = 0.0005). This study provides knowledge on cytokine composition in the subdural fluid in patients with CSDH with and without recurrence. IL-1ra is elevated in subdural fluid in patients with recurrent CSDH at the time of the second operation, identifying a possible medical target.",

keywords = "Chemokines, Chronic subdural hematoma, Cytokines, Hematoma fluid, IL-1ra, Recurrence",

author = "Jensen, {Thorbj{\o}rn S{\o}ren R{\o}nn} and Tina Binderup and Olsen, {Markus Harboe} and Andreas Kjaer and K{\aa}re Fugleholm",

note = "Publisher Copyright: {\textcopyright} 2023, The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.",

year = "2023",

doi = "10.1007/s10753-023-01811-8",

language = "English",

volume = "46",

pages = "1332–1342",

journal = "Inflammation",

issn = "0360-3997",

publisher = "Springer",

}

RIS

TY - JOUR

T1 - Subdural Levels of Interleukin 1-receptor Antagonist are Elevated in Patients with Recurrent Chronic Subdural Hematomas

AU - Jensen, Thorbjørn Søren Rønn

AU - Binderup, Tina

AU - Olsen, Markus Harboe

AU - Kjaer, Andreas

AU - Fugleholm, Kåre

PY - 2023

Y1 - 2023

N2 - Anti-inflammatory treatment reduces the risk of recurrent chronic subdural hematoma (CSDH), but clinical implementation is improper due to side effects. Exact knowledge of subdural molecules involved in recurrent CSDH may lead to targeted medical treatment and possibly improve the prospect of a personalized approach by eliminating the broad use of anti-inflammatory drugs on the entire CSDH population. With this study, we aim to (1) describe the associations between cytokine levels at the primary surgery and the risk of subsequent recurrence and (2) describe the association between cytokines in patients with recurrent CSDH between the first and second operations. Systemic and subdural levels of pro- and anti-inflammatory cytokines were measured and compared between patients with the first-time CSDH and recurrent CSDH. Cytokine levels were analyzed using a multiplex antibody bead kit. In case of recurrent CSDH within 90 days of follow-up, the samples were re-collected and analyzed. We included 101 adult CSDH patients of which 20 had a recurrence. The levels of cytokines in the CSDH fluid from patients who were operated on for the first-time CSDH were not associated with the risk of later developing a recurrence. We found interleukin-1 receptor antagonist (IL-1ra) to be elevated in subdural fluid in patients with recurrent CSDH at the time of their second operation (p = 0.0005). This study provides knowledge on cytokine composition in the subdural fluid in patients with CSDH with and without recurrence. IL-1ra is elevated in subdural fluid in patients with recurrent CSDH at the time of the second operation, identifying a possible medical target.

AB - Anti-inflammatory treatment reduces the risk of recurrent chronic subdural hematoma (CSDH), but clinical implementation is improper due to side effects. Exact knowledge of subdural molecules involved in recurrent CSDH may lead to targeted medical treatment and possibly improve the prospect of a personalized approach by eliminating the broad use of anti-inflammatory drugs on the entire CSDH population. With this study, we aim to (1) describe the associations between cytokine levels at the primary surgery and the risk of subsequent recurrence and (2) describe the association between cytokines in patients with recurrent CSDH between the first and second operations. Systemic and subdural levels of pro- and anti-inflammatory cytokines were measured and compared between patients with the first-time CSDH and recurrent CSDH. Cytokine levels were analyzed using a multiplex antibody bead kit. In case of recurrent CSDH within 90 days of follow-up, the samples were re-collected and analyzed. We included 101 adult CSDH patients of which 20 had a recurrence. The levels of cytokines in the CSDH fluid from patients who were operated on for the first-time CSDH were not associated with the risk of later developing a recurrence. We found interleukin-1 receptor antagonist (IL-1ra) to be elevated in subdural fluid in patients with recurrent CSDH at the time of their second operation (p = 0.0005). This study provides knowledge on cytokine composition in the subdural fluid in patients with CSDH with and without recurrence. IL-1ra is elevated in subdural fluid in patients with recurrent CSDH at the time of the second operation, identifying a possible medical target.

KW - Chemokines

KW - Chronic subdural hematoma

KW - Cytokines

KW - Hematoma fluid

KW - IL-1ra

KW - Recurrence

U2 - 10.1007/s10753-023-01811-8

DO - 10.1007/s10753-023-01811-8

M3 - Journal article

C2 - 37039933

AN - SCOPUS:85152376968

VL - 46

SP - 1332

EP - 1342

JO - Inflammation

JF - Inflammation

SN - 0360-3997

ER -

ID: 345123070